Blood tests for heart injury after stent procedures in coronary artery disease
Checks blood markers of heart injury in adults getting stents for coronary artery disease.
Plain-language title generated from the registry record
Registry title: Clinical Evidence With Biomarker Confirmation for PPMI in PCI Clinical Trials Study
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Baim Institute for Clinical ResearchBoston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Baim Institute for Clinical Research
- Trial code
- NCT07848529
- Record updated
- 30 September 2026
- Original description
The goal of this prospective, multicenter, non-randomized observational study is to better identify and understand periprocedural myocardial injury among adults undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease or stabilized non-ST-elevation acute coronary syndrome. The main questions it aims to answer are:Read full original descriptionShow less
Clinical Evidence With Biomarker Confirmation for PPMI in PCI Clinical Trials Study
The goal of this prospective, multicenter, non-randomized observational study is to better identify and understand periprocedural myocardial injury among adults undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease or stabilized non-ST-elevation acute coronary syndrome. The main questions it aims to answer are:
* Can a clinical criteria checklist identify patients with an increased likelihood of cardiac biomarker elevation following PCI? * Are positive clinical criteria and different post-PCI levels of troponin I, troponin T, and CK-MB associated with all-cause mortality or hospitalization for heart failure at one year? Researchers will compare participants with a positive clinical criteria checklist with those with a negative checklist to assess differences in post-PCI biomarker elevations and one-year clinical outcomes. Outcomes will also be compared between participants discharged on the same day and those hospitalized overnight.
Participants will:
* Undergo PCI using commercially approved devices according to local standards of care. * Have blood samples collected before and after PCI to measure cardiac biomarkers. * Have relevant clinical and PCI procedural information collected, including completion of a clinical criteria checklist by the study team before discharge. * Be followed for one year to determine whether they have died from any cause or been hospitalized for heart failure.
Inclusion: Subject age is ≥ 18 years or minimum legal age as required by local regulations; Documented stable angina or functional testing demonstrating ischemia; or stabilized non-ST elevation acute coronary syndrome defined as negative or confirmed declining site determined biomarker; Subject is eligible for dual anti-platelet therapy treatment with aspirin plus either, clopidogrel, prasugrel, or ticagrelor; Life expectancy >1 year in opinion of investigator; Subject is willing and able to provide informed consent and comply with study procedures and required follow-up evaluations.
Exclusion: Previous percutaneous coronary intervention within 7 days; ST elevation myocardial infarction within 7 days; Non-ST elevation myocardial infarction without stable or declining biomarkers; Decompensated heart failure; Inability to comply with recommended duration of dual anti-platelet therapy.